SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
 and Lead Plaintiff Deadline: November 21, 2016 - EconoTimes)
NEW YORK, Oct. 14, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased Spectrum securities between December 16, 2015 through September 16, 2016, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the “FDA”) previously questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA instructed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) consequently, defendants’ public statements regarding the Company’s business, operations and prospects were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sppi or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Spectrum you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
